Further outcomes included age and prostate-specific antigen level at diagnosis, initial treatment modality, time from diagnosis to initial treatment, and prostate cancer–specific, metastasis-free, and overall survivals. This evidence concerns the gene KLK3 and Familial prostate cancer.